Drug delivery deals reflect biologics progress
This article was originally published in Scrip
While most drug delivery deal-making traditionally revolves around products that have been launched or specialty products to extend and protect a product's market position, a new study from the Indian consulting and investment advisory firm, MP Advisors, suggests a growing trend for early stage agreements.
You may also be interested in...
Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.